Is glyburide safe in pregnancy?

Current Pharmaceutical Biotechnology

Volumn 15, Issue 1, 2014, Pages 100-112

  Kimber Trojnar, Zaneta ^a   Marciniak, Beata ^a   Patro Małysza, Jolanta ^a   Skórzyńska Dziduszko, Katarzyna ^a   Poniedziałek Czajkowska, Elzbieta ^a   Mierzyński, Radzisław ^a   Gałczyński, Krzysztof ^a   Trojnar, Marcin ^a   Leszczyńska Gorzelak, Bozena ^a   Oleszczuk, Jan ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Gestational diabetes; Glibenclamide; Glucose control; Glyburide; Placenta; Pregnancy

Indexed keywords

GLIBENCLAMIDE; ANTIDIABETIC AGENT;

BLOOD BRAIN BARRIER; BLOOD GLUCOSE MONITORING; BREAST MILK; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; MASS SPECTROMETRY; NONHUMAN; PREGNANCY; PREGNANCY DIABETES MELLITUS; REVIEW; ANIMAL; DIABETES, GESTATIONAL; FEMALE; FETOMATERNAL TRANSFUSION; METABOLISM; PLACENTA;

ANIMALS; DIABETES, GESTATIONAL; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MATERNAL-FETAL EXCHANGE; MILK, HUMAN; PLACENTA; PREGNANCY;

EID: 84904717704     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140330200254     Document Type: Review

References (130)

1. Paglia, M. J.; Coustan, D. R. The use of oral antidiabetic medications in gestational diabetes mellitus. Curr. Diabetes Rep., 2009, 9, 287-290.
2. Beischer, N. A.; Oats, J. N.; Henry, O. A.; Sheedy, M. T.; Walstab, J. E. Incidence and severity of gestational diabetes mellitus according to country of birth in women living in Australia. Diabetes, 1991, 40(Suppl. 2), 35-38.
3. Jovanovic, L.; Pettitt, D. J. Gestational diabetes mellitus. JAMA, 2001, 286, 2516-2518.
4. Ferrara, A.; Kahn, H. S.; Quesenberry, C. P.; Riley, C.; Hedderson, M. M. An increase in the incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstet. Gynecol., 2004, 103, 526-533.
5. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997, 20, 1183-1197.
6. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care, 2013, 36(Suppl. 1), S11-S66.
7. Lawrence, J. M.; Contreras, R.; Chen, W.; Sacks, D. A. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care, 2008, 31, 899-904.
8. Durnwald, C; Landon, M. B. Glyburide: the new alternative for treating gestational diabetes? [Editorial]. Am. J. Obstet. Gynecol., 2005, 193, 1-2.
9. th ed.; Urban und Fischer: München, 2012.
10. Refuerzo, J. S. Oral hypoglycemic agents in pregnancy. Obstet. Gynecol. Clin. North Am., 2011, 38, 227-234.
11. Langer, O.; Yogev, Y.; Xenakis, E. M.; Rosenn, B. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am. J. Obstet. Gynecol., 2005, 192, 134-139.
12. O'Sullivan, J. B. The epidemiology of cardiovascular disease and diabetes mellitus in perspective. Mt. Sinai J. Med.; 1982, 49(3), 163-168.
13. England, L. J.; Dietz, P. M.; Njoroge, T.; Callaghan, W. M.; Bruce, C.; Buus, R. M.; Williamson, D. F. Preventing type 2 diabetes: public health implications for women with a history of gestational diabetes mellitus. Am. J. Obstet. Gynecol., 2009, 200(4), 365. e1-365. e8.
14. American College of Obstetricians and Gynecologists. Gestational diabetes mellitus. Committee on Practice Bulletins-Obstetrics, Practice Bulletin No. 137. Obstet. Gynecol., 2013, 122(2 Pt 1), 406-416.
15. Lee-Parritz, A. Contemporary management of gestational diabetes. Curr. Opin. Endocrinol. Diabetes Obes., 2011, 18, 395-400.
16. Jacobson, G. F.; Ramos, G. A.; Ching, J. Y.; Kirby, R. S.; Ferrara, A.; Field, D. R. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am. J. Obstet. Gynecol.; 2005, 193, 118-124.
17. Zucker, P.; Simon, G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics, 1968, 42(5), 824-825.
18. Piacquadio, K.; Hollingsworth, D. R.; Murphy, H. Effects of inutero exposure to oral hypoglycaemic drugs. Lancet, 1991, 338, 866-869.
19. Groop, L.; Barzilai, N.; Ratheiser, K.; Luzi, L.; Wahlin-Boll, E.; Melander, A.; DeFronzo, R. A. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care, 1991, 14, 724-727.
20. Greene, M. F. Oral hypoglycemic drugs for gestational diabetes. N. Engl. J. Med.; 2000, 343, 1178-1179.
21. Reece, E. A.; Homko, C.; Miodovnik, M.; Langer, O. A consensus report of the Diabetes in Pregnancy Study Group of North America Conference, Little Rock, Arkansas, May 2002. J. Matern. Fetal Neonatal Med.; 2002, 12, 362-364.
22. Gabbe, S. G.; Graves, C. R. Management of diabetes mellitus complicating pregnancy. Obstet. Gynecol., 2003, 102, 857-868.
23. Saade, G. Gestational diabetes mellitus: a pill or a shot? Obstet. Gynecol.; 2005, 105(3), 456-457.
24. Gabbe, S. G.; Gregory, R. P.; Power, M. L.; Williams, S. B.; Schulkin, J. Management of diabetes mellitus by obstetriciangynecologists. Obstet. Gynecol., 2004, 103, 1229-1234.
25. Cheng, Y. W.; Chung, J. H.; Block-Kurbisch, I.; Inturrisi, M.; Caughey, A. B. Treatment of gestational diabetes mellitus: oral hypoglycemic agents compared to subcutaneous insulin therapy. Am. J. Obstet. Gynecol., 2007, 195, S36.
26. Rowan, J. A.; Hague, W. M.; Gao, W.; Battin, M. R.; Moore, M. P. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N. Engl. J. Med., 2008, 358, 2003-2015.
27. + channel. Pol. J. Pharmacol., 1993, 45(4), 437-443.
28. Gedeon, C.; Koren, G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta, 2006, 27, 861-868.
29. Groop, L.; Luzi, L.; Melander, A.; Groop, P. H.; Ratheiser, K.; Simonson, D. C.; DeFronzo, R. A. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes, 1987, 36, 1320-1328.
30. DeFronzo, R. A.; Simonson, D. C. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care, 1984, 7(Suppl. 1), 72-80.
31. Rossetti, L.; Giaccari, A.; DeFronzo, R. A. Glucose toxicity. Diabetes Care, 1990, 13, 610-630.
32. Kalra, S.; Mukherjee, J. J.; Venkataraman, S.; Bantwal, G.; Shaikh, S.; Saboo, B.; Das, A. K.; Ramachandran, A. Hypoglycemia: The neglected complication. Indian J. Endocrinol. Metab., 2013, 17(5), 819-834.
33. Ahmed, S. S.; Laila, T. R. Medications for hyperglycemia in type 2 diabetes and review of insulin degludec and dapagliflozin. Int. J. Pharm. Sci. Inv., 2014, 3(1), 26-35, http://www. ijpsi. org/Papers/Vol3%281%29/D031026035. pdf.
34. Inzucchi, S. E.; Bergenstal, R. M.; Buse, J. B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A. L.; Tsapas, A.; Wender, R.; Matthews, D. R. American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012, 35(6), 1364-1379.
35. Rosenstock, J.; Marx, N.; Kahn, S. E.; Zinman, B.; Kastelein, J. J.; Lachin, J. M.; Bluhmki, E.; Patel, S.; Johansen, O. E.; Woerle, H. J. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab. Vasc. Dis. Res., 2013, 10(4), 289-301.
36. Juurlink, D. N.; Gomes, T.; Shah, B. R.; Mamdani, M. M. Adverse cardiovascular events during treatment with glyburide in a highrisk population. Diabet. Med., 2012, 29(12), 1524-1528.
37. Jørgensen, C. H.; Gislason, G. H.; Bretler, D.; Sørensen, R.; Norgaard, M. L.; Hansen, M. L.; Schramm, T. K.; Abildstrom, S. Z.; Torp-Pedersen, C.; Hansen, P. R. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study. Int. J. Cardiol., 2011, 152(3), 327-331.
38. Malmberg, K. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br. Med. J., 1997, 314, 1512-1515.
39. Abdelmoneim, A. S.; Eurich, D. T.; Gamble, J. M.; Johnson, J. A.; Seubert, J. M.; Qiu, W.; Simpson, S. H. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes. Metab., 2014, 16(1), 22-29.
40. Sheth, K. N.; Kimberly, W. T.; Elm, J. J.; Kent, T. A.; Mandava, P.; Yoo, A. J.; Thomalla, G.; Campbell, B.; Donnan, G. A.; Davis, S. M.; Albers, G. W.; Jacobson, S.; Simard, J. M.; Stern, B. J. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke, http://www. ncbi. nlm. nih. gov/pubmed/24193798 2014, 45(1), 281-283.
41. Rydberg, T.; Jönsson, A.; Karlsson, M. O.; Melander, A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol., 1997, 43(3), 373-381.
42. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J.; Kivisto, K. T. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther., 2001, 69, 400-406.
43. Langer, O. Oral hypoglycemic agents and the pregnant diabetic: "from bench to bedside". Semin. Perinatol., 2002, 26, 215-24.
44. Caritis, S. N.; Hebert, M. F. A pharmacologic approach to the use of glyburide in pregnancy. Obstet. Gynecol., 2013, 121(6), 1309-1312.
45. Koren, G. Glyburide and fetal safety; trans-placental pharmacokinetic considerations. Reprod. Toxicol., 2001, 15, 227-229.
46. Rydberg, T.; Jönsson, A.; Røder, M.; Melander, A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care, 1994, 17(9), 1026-1030.
47. Rydberg, T.; Jönsson, A.; Melander, A. Comparison of the kinetics of glyburide and its active metabolites in humans. J. Clin. Pharm. Ther., 1995, 20(5), 283-295.
48. Kirchheiner, J.; Brockmoller, J.; Meineke, I.; Bauer, S.; Rohde, W.; Meisel, C.; Roots, I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther., 2002, 71, 286-296.
49. Zharikova, O. L.; Ravindran, S.; Nanovskaya, T. N.; Hill, R. A.; Hankins, G. D.; Ahmed, M. S. Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. Biochem. Pharmacol., 2007, 73(12), 2012-2019.
50. Ravindran, S.; Gorti, S. K.; Basu, S.; Surve, P.; Honrao, P. differences and similarities in the metabolism of glyburide for various species: An analysis by LC-DAD-Q-TRAP-MS/MS. J. Anal. Bioanal. Techniques, 2013, 4(2), 164.
51. Ravindran, S.; Basu, S.; Gorti, S. K.; Surve, P.; Sloka, N. Metabolic profile of glyburide in human liver microsomes using LC-DAD-QTRAP-MS/MS. Biomed. Chromatogr., 2013, 27(5), 575-582.
52. Hebert, M. F.; Ma, X.; Naraharisetti, S. B.; Krudys, K. M.; Umans, J. G.; Hankins, G. D.; Caritis, S. N.; Miodovnik, M.; Mattison, D. R.; Unadkat, J. D.; Kelly, E. J.; Blough, D.; Cobelli, C.; Ahmed, M. S.; Snodgrass, W. R.; Carr, D. B.; Easterling, T. R.; Vicini, P. Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin. Pharmacol. Ther., 2009, 85(6), 607-614.
53. Jönsson, A.; Rydberg, T.; Ekberg, G.; Hallengren, B.; Melander, A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care, 1994, 17(2), 142-145.
54. rd ed.; Lippincott Williams & Wilkins: Philadelphia, 1995, 165-168.
55. Zhou, L.; Zhang, Y.; Hebert, M. F.; Unadkat, J. D.; Mao, Q. Increased glyburide clearance in the pregnant mouse model. Drug Metab Dispos., 2010b, 38(9), 1403-1406.
56. Zhou, L.; Naraharisetti, S. B.; Liu, L.; Wang, H.; Lin, Y. S.; Isoherranen, N.; Unadkat, J. D.; Hebert, M. F.; Mao, Q. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm. Drug Dispos., 2010a, 31(4), 228-242.
57. Naritomi, Y.; Terashita, S.; Kagayama, A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica, 2004, 34, 415-427.
58. Zharikova, O. L.; Fokina, V. M.; Nanovskaya, T. N.; Hill, R. A.; Mattison, D. R.; Hankins, G. D.; Ahmed, M. S. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem. Pharmacol., 2009, 78(12), 1483-1490.
59. Lilja, J. J.; Niemi, M.; Fredrikson, H.; Neuvonen, P. J. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol., 2007, 63, 732-740.
60. Shuster, D. L.; Hebert, M. F.; Mao, Q. Glyburide Disposition During Pregnancy, Gestational Diabetes, Prof. Miroslav Radenkovic (Ed.), 2011, ISBN: 978-953-307-581-5, InTech, http://www. intechopen. com/books/gestational-diabetes/glyburidedisposition-during-pregnancy.
61. Jain, S.; Zharikova, O.; Ravindran, S.; Nanovskaya, T.; Hankins, G. D.; Ahmed, M. S. Metabolism of glibenclamide (glyburide) by human placenta. Am. J. Obstet. Gynecol., 2005, 193, S91.
62. Jain, S.; Zharikova, O. L.; Ravindran, S.; Nanovskya, T. N.; Mattison, D. R.; Hankins, G. D.; Ahmed, M. S. Glyburide metabolism by placentas of healthy and gestational diabetics. Am. J. Perinatol., 2008, 25(3), 169-174.
63. Ravindran, S.; Zharikova, O. L.; Hill, R. A.; Nanovskaya, T. N.; Hankins, G. D.; Ahmed, M. S. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem. Pharmacol., 2006, 72(12), 1730-1737.
64. Daskalakis, G.; Marinopoulos, S.; Krielesi, V.; Papapanagiotou, A.; Papantoniou, N.; Mesogitis, S.; Antsaklis, A. Placental pathology in women with gestational diabetes. Acta Obstet. Gynecol. Scand., 2008, 87(4), 403-407.
65. Cygalova, L. H.; Hofman, J.; Ceckova, M.; Staud, F. Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J. Pharmacol. Exp. Ther., 2009, 331(3), 1118-1125.
66. Garcia-Bournissen, F.; Feig, D. S.; Koren, G. Maternal-fetal transport of hypoglycaemic drugs. Clin. Pharmacokinet., 2003, 42, 303-313.
67. Ganapathy, V.; Prasad, P. D.; Ganapathy, M. E.; Leibach, F. H. Placental transporters relevant to drug distribution across the maternalfetal interface. J. Pharmacol. Exp. Ther., 2000, 294(2), 413-420.
68. Syme, M. R.; Paxton, J. W.; Keelan, J. A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet., 2004, 43(8), 487-514.
69. St-Pierre, M. V.; Serrano, M. A.; Macias, R. I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P. J.; Marin, J. J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(4), R1495-R1503.
70. Flens, M. J.; Zaman, G. J.; van der Valk, P.; Izquierdo, M. A.; Schroeijers, A. B.; Scheffer, G. L.; van der Groep, P.; de Haas, M.; Meijer, C. J.; Scheper, R. J. Tissue distribution of the multidrug resistanceassociated protein. Am. J. Pathol., 1996, 148(4), 1237-1247.
71. Nakamura, Y.; Ikelda, S.; Fukuwara, T.; Sumizawa, T.; Tani, A.; Akiyama, S. Function of P-glycoprotein expressed in the placenta and mole. Biochem. Bioph. Res. Co., 1997, 235, 849-853.
72. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C.; Schinkel, A. H.; van De Vijver, M. J.; Scheper, R. J.; Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61(8), 3458-3464.
73. Hemauer, S. J.; Patrikeeva, S. L.; Nanovskaya, T. N.; Hankins, G. D. V.; Ahmed, M. S. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am. J. Obstet. Gynecol., 2010, 202(4), 383. e1-383. e7.
74. Elliott, B. D.; Langer, O.; Schenker, S.; Johnson, R. F. Insignificant transfer of glyburide occurs across the human placenta. Am. J. Obstet. Gynecol., 1991, 165, 807-812.
75. Elliott, B. D.; Schenker, S.; Langer, O.; Johnson, R.; Prihoda, T. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am. J. Obstet. Gynecol., 1994, 171, 653-660.
76. Langer, O.; Conway, D. L.; Berkus, M. D.; Xenakis, E. M.; Gonzales, O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med., 2000, 343, 1134-1138.
77. Nanovskaya, T. N.; Nekhayeva, I.; Hankins, G. D.; Ahmed, M. S. Effect of human serum albumin on transplacental transfer of glyburide. Biochem. Pharmacol., 2006, 72, 632-639.
78. Nanovskaya, T. N.; Mattison, D. R.; Hankins, G. D.; Ahmed, M. S. Glyburide metabolism by placentas of healthy and gestational diabetics. Am. J. Perinatol., 2008, 25(3), 169-174.
79. Gerich, J. E. Oral hypoglycemic agents. N. Engl. J. Med., 1989, 321, 1231-1245.
80. Kraemer, J.; Klein, J.; Lubetsky, A.; Koren, G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am. J. Obstet. Gynecol., 2006, 195, 270-274.
81. Gedeon, C.; Behravan, J.; Koren, G.; Piquette-Miller, M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta, 2006, 27, 1096-1102.
82. Gedeon, C.; Anger, G.; Piquette-Miller, M.; Koren, G. Breast cancer resistance protein: Mediating the trans-placental transfer of glyburide across the human placenta. Placenta, 2008, 29, 39-43.
83. Pollex, E.; Lubetsky, A.; Koren, G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta, 2008, 29, 743-747.
84. Zhou, L.; Naraharisetti, S. B.; Wang, H.; Unadkat, J. D.; Hebert, M. F.; Mao, Q. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Ob stetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol. Pharmacol., 2008, 73(3), 949-959.
85. Sivan, E.; Feldman, B.; Dolitzki, M.; Nevo, N.; Dekel, N.; Karasik, A. Glyburide crosses the placenta in vivo in pregnant rats. Diabetologia, 1995, 38(7), 753-756.
86. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta, 1999, 1461(2), 347-357.
87. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistanceassociated proteins. J. Natl. Cancer Inst., 2000, 92, 1295-1302.
88. De Boer, A. G.; van der Sandt, I. C.; Gaillard, P. J. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 629-656.
89. Kusch-Poddar, M.; Drewe, J.; Fux, I.; Gutmann, H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-brain barrier. Brain Research, 2005, 1064, 21-31.
90. Feig, D. S.; Briggs, G. G.; Kraemer, J. M.; Ambrose, P. J.; Moskovitz, D. N.; Nageotte, M.; Donat, D. J.; Padilla, G.; Wan, S.; Klein, J.; Koren, G. Transfer of glyburide and glipizide into breast milk. Diabetes Care, 2005, 28(8), 1851-1855.
91. Feig, D. S.; Briggs, G. G.; Koren, G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann. Pharmacother., 2007, 41, 1174-1180.
92. Glatstein, M. M.; Djokanovic, N.; Garcia-Bournissen, F.; Finkelstein, Y.; Koren, G. Use of hypoglycemic drugs during lactation. Canadian Family Physician, 2009, 55, Published Motherisk Updates are available on: www. cfp. ca and www. motherisk. org.
93. Bertini, A. M.; Silva, J. C.; Taborda, W.; Becker, F.; Lemos Bebber, F. R.; Zucco Viesi, J. M.; Aquim, G.; Engel Ribeiro, T. Perinatal outcomes and the use of oral hypoglycemic agents. J. Perinat. Med., 2005, 33, 519-523.
94. Silva, J. C.; Bertini, A. M.; Taborda, W.; Becker, F.; Bebber, F. R. L.; Aquim, G. M. D. C.; Viesi, J. M. Z. Glibenclamida no tratamento do diabete melito gestacional em estudo comparado a insulina. [Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin]. Arq. Bras. Endocrinol. Metab., 2007, 51(4), 541-546.
95. Lain, K. Y.; Garabedian, M. J.; Daftary, A.; Jeyabalan, A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am. J. Obstet. Gynecol., 2009, 200(5), 501. e1-501. e6.
96. Anjalakshi, C.; Balaji, V.; Balaji, M. S.; Seshiah, V. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res. Clin. Pract., 2007, 76(3), 474-475.
97. Ogunyemi, D.; Jesse, M.; Davidson, M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus [Letter to the editor]. Endocr. Pract., 2007, 13, 427-428.
98. Silva, J. C.; Fachin, D. R.; Coral, M. L.; Bertini, A. M. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J. Perinat. Med.; 2012, 40(3), 225-228.
99. Yogev, Y.; Ben-Haroush, A.; Chen, R.; Rosenn, B.; Hod, M.; Langer, O. Undiagnosed asymptomatic hypoglycemia: diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet. Gynecol., 2004, 104(1), 88-93.
100. Ramos, G. A.; Jacobson, G. F.; Kirby, R. S.; Ching, J. Y.; Field, D. R. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J. Perinatol., 2007, 27(5), 262-267.
101. Chmait, R.; Dinise, T.; Daneshmand, S.; Kim, M.; Moore, T. Prospective cohort study to establish predictors of glyburide success in women with gestational diabetes mellitus. Am. J. Obstet. Gynecol., 2001, 185, S197.
102. Chmait, R.; Dinise, T.; Moore, T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J. Perinatol.; 2004, 24, 617-622.
103. Tempe, A.; Mayanglambam, R. D. Glyburide as treatment option for gestational diabetes mellitus. J. Obstet. Gynaecol. Res., 2013, 39(6), 1147-1152.
104. Lim, J. M.; Tayob, Y.; O'Brien, P. M. S.; Shaw, R. W. A comparison between the pregnancy outcome of women with gestation diabetes treated with glibenclamide and those treated with insulin. Med. J. Malaysia, 1997, 52, 377-381.
105. Gilson, G.; Murphy, N. Comparison of oral glyburide with insulin for the management of gestational diabetes mellitus in Alaska native women. Am. J. Obstet. Gynecol., 2002, 187(6 Suppl.), S152.
106. Fines, V.; Moore, T.; Castle, S. A comparison of glyburide and insulin treatment in gestational diabetes mellitus on infant birth weight and adiposity. Am. J. Obstet. Gynecol., 2003, 189(6 Suppl.), S108.
107. Coetzee, E. J.; Jackson, W. P. The management of noninsulindependent diabetes during pregnancy. Diabetes Res. Clin. Pract., 1985-1986, 1, 281-287.
108. Mathews, J. E.; Biswas, B.; Samuel, P.; Jana, A. K.; Muliyil, J. P.; Mathai, M. Retrospective cohort study comparing neonatal outcomes of women treated with glyburide or insulin in gestational diabetes: a 5-year experience in a South Indian teaching hospital. Indian J. Med. Sci., 2011, 65(11), 476-481.
109. Rochon, M.; Rand, L.; Roth, L.; Gaddipati, S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am. J. Obstet. Gynecol., 2006, 195, 1090-1094.
110. Kremer, C. J.; Duff, P. Glyburide for the treatment of gestational diabetes. Am. J. Obstet. Gynecol., 2004, 190, 1438-1439.
111. Conway, D. L.; Gonzales, O.; Skiver. D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J. Matern. Fetal Neonatal Med., 2004, 15, 51-55.
112. Kahn, B. F.; Davies, J. K.; Lynch, A. M.; Reynolds, R. M.; Barbour, L. A. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet. Gynecol., 2006, 107, 1303-1309.
113. Cheng, Y. W.; Chung, J. H.; Block-Kurbisch, I.; Inturrisi, M.; Caughey, A. B. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J. Matern. Fetal Neonatal Med., 2012, 25(4), 379-384.
114. Velazquez, M. D.; Bolnick, J.; Cloakey, D.; Gonzalez, J. L.; Curet, L. B. The use of glyburide in the management of gestational diabetes. Obstet. Gynecol., 2003, 101(Suppl.), 88S.
115. Rosenn, B. M. The glyburide report card. J. Matern. Fetal Neonatal Med., 2010, 23(3), 219-223.
116. Berggren, E. K.; Boggess, K. A. Oral agents for the management of gestational diabetes. Clin. Obstet. Gynecol., 2013, 56(4), 827-836.
117. Dhulkotia, J. S.; Ola, B.; Fraser, R.; Farrell, T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am. J. Obstet. Gynecol., 2010, 203(5), 457. e1-457. e9.
118. Kimber-Trojnar, Ż, Marciniak, B.; Leszczyńska-Gorzelak, B.; Trojnar, M.; Oleszczuk, J. Glyburide for the treatment of gestational diabetes mellitus. Pharmacol. Rep., 2008, 60(3), 308-318.
119. Ross, M. G.; Kjos, S. L. Glyburide: caution for efficacy and fetal programming effects. Am. J. Obstet. Gynecol., 2010, 202(4), e8.
120. Plitzko, D.; Rumpel, S.; Gottmann, K. Insulin promotes functional induction of silent synapses in differentiating rat neocortical neurons. Eur. J. Neurosci., 2001, 14, 1412-1415.
121. Naylor, C. D.; Sermer, M.; Chen, E.; Sykora, K. Cesarean delivery in relation to birth weight and gestational glucose tolerance: pathophysiology or practice style? Toronto Trihospital Gestational Diabetes Investigators. JAMA, 1996, 275, 1165-1170.
122. Hellmuth, E.; Damm, P.; Molsted-Pedersen, L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet. Med., 2000, 17, 507-511.
123. Ebeigbe, A. B.; Cabanie, M. In vitro vascular effects of cicletanine in pregnancy-induced hypertension. Br. J. Pharmacol., 1991, 103, 1992-996.
124. Keyes, L.; Rodman, D. M.; Curran-Everett, D.; Morris, K.; Moore, L. G. Effect of K channel inhibition on total and regional vascular resistance in guinea pig pregnancy. Am. J. Physiol., 1998, 275, H680-H688.
125. Khouzami, V. A.; Ginsburg, D. S.; Daikoku, N. H.; Johnson, J. W. The glucose tolerance test as a means of identifying intrauterine growth retardation. Am. J. Obstet. Gynecol., 1981, 139, 423-426.
126. Langer, O.; Damus, K.; Maiman, M.; Divon, M.; Levy, J.; Bauman, W. A link between relative hypoglycemiahypoinsulinemia during oral glucose tolerance tests and intrauterine growth retardation. Am. J. Obstet. Gynecol., 1986, 155, 711-716.
127. Sokol, R. J.; Kazzi, G. M.; Kalhan, S. C.; Pillay, S. K. Identifying the pregnancy at risk for intrauterine growth retardation: possible usefulness of the intravenous glucose tolerance test. Am. J. Obstet. Gynecol., 1982, 143(2), 220-223.
128. Bjorklund, A. O.; Adamson, U. K.; Almstrom, N. H.; Enocksson, E. A.; Gennser, G. M.; Lins, P. E.; Westgren, L. M. Effects of hypoglycaemia on fetal heart activity and umbilical artery Doppler velocity waveforms in pregnant women with insulin-dependent diabetes mellitus. Br. J. Obstet. Gynaecol., 1996, 103, 413-420.
129. Reece, E. A.; Homko, C. J. Diabetes mellitus in pregnancy. What are the best treatment options? Drug Saf., 1998, 18, 209-220.
130. Boney, C. M.; Verma, A.; Tucker, R.; Vohr, B. R. Metabolic syndrome in childhood: Association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics, 2005, 115, e290-e296.